Kulkarni Samarth 4
4 · CRISPR Therapeutics AG · Filed Oct 20, 2025
Insider Transaction Report
Form 4
Kulkarni Samarth
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Shares
2025-10-16+100,000→ 305,096 total - Sale
Common Shares
2025-10-17$67.91/sh−50,895$3,456,279→ 254,201 total - Exercise/Conversion
Restricted Stock Units
2025-10-16−100,000→ 300,000 total→ Common Shares (100,000 underlying)
Holdings
- 85,662(indirect: The Kulkarni 2023 GRAT)
Common Shares
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on October 16, 2024 with respect to 400,000 Common Shares, with (i) one quarter of the shares vesting on October 16, 2025, (ii) one quarter of the shares vesting on October 16, 2026, (iii) one quarter of the shares vesting on October 16, 2027, and (iv) one quarter of the shares vesting on October 16, 2028.